Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Oak tree, I wholeheartedly agree.
I’ve been trying to work out why Kurt has been so underwhelming. I concluded that he is (as he says ) an operator and not a developer of mines and he’s been paralysed be indecision by the situation without experience to draw on
sentiment around the whole market is poor, around small cap biotech it has been poor for a long time. Vlad may be confident but that isn't the same as market sentiment.
Options for buyers include:
large Pharma/biotech buying small biotech
Large pharma buying small biotechs' 'products'
Biotech funds buying in - requires iis and pis to give them money
So (with due respect to Pumpky) him spending his holiday money here (or not) won't make a jot of difference
.... of some small cap biotech activity in the US, valuations still chronically low with many at caps below cash but there are some headlines drawing interest. re rates only come with buyers, watch for buyers, watch for changing sentiment
MrIndia,
I certainly done hate you nor even dislike you but you do frustrate me - I am sure others feel the same as I do as well - and I think when I or others respond to you it is in frustration rather than anything more malevolent.
I don't Vlad doesn't care about shareholders, he is one himself after all, but I do think he has realised there are things he can't control (SP) and things he can (hemo) and is focusing as such. I am not saying he is a particularly shareholder centric CEO though
Finally I don't believe Hemo's future is entirely in its hands as I believe the 'market' is hugely important also. That said I hope/expect this bear market to end and biotech to return to fashion as investors look for breakout returns in 2023.
So here's to a better 2023, something we can all get behind.
p.s. Ive no idea if Tuan is a deramper or not as I've never been able to understand a single sentence they have written
Pumpky,
1. Money is flowing out of equities - the big money is v v defensive right now - see BoA Fund Managers Survey
2. Particularly so for speculative growth stocks - read commentary from Biotech fund managers
3. US investors are crystallising losses ( to offset any gains) by year end - may buy back in Jan?
4. I hold Marker, Jounce, Purple, Gritstone and Hemo - all down similar %s. Vlad knows he can't fight the market so (I hope) is focusing on the science
MrIndia,
The silliest thing on this board (by a mile) is you. You appear emotionally unstable and have less understanding of shares and the markets than the hedgehog in my garden. You are an utter buffoon. Sorry to be rude but its true
I know many of you believe hemo’s future is entirely in hemo/class hands whereas I believe it’s about net flows in to biotech (as much as the science) . With that in mind I copied this from “the daily rip”
…..
There are three charts that the community has been talking about recently, so we want to highlight them below with some context.
The first is the market-cap weighted iShares Biotech ETF ($IBB).
Technical analysts have pointed to the base it formed throughout 2022, with prices staying below the 135-137 level. But as of this week, many suggest a breakout is ahead for the sector as prices test that resistance level once again.
So why does this matter?
Bulls say the Biotech sector is often a leading indicator for bull markets. The theory is this higher-beta area of the market shows investor risk appetite and willingness to bet on higher prices for the overall stock market. Bears question that theory and think this breakout attempt will fail like all the last as the overall market turns lower again.
Only time will tell who is right. But for now, Biotech remains on many community members’ radars. ??
MRIndia, even if every last one of us on this board was positive the sp wouldn't go up. What drives the sp is more buyers than sellers and we need buyers who want 10's of millions of shares, not a few hundred 000 or even a couple of million. its serious buyers you want, not us PIs
Thank you jhfh.
I do believe the tide will turn and I’m daring to hope quite soon. I haven’t an effing clue what the boe and fed are doing raising interest rates, it’s a supply side issue not a demand side as far as I can see and when they realise that and stop driving us in to recession the money will flow back in.
Also people are nervous of tech and so I hope they look to biotech for big gains. I am hopeful 2023 will be a good year for us
Jhfh,
Yes marker are another one of my choices that I regret. Sticking with them as I’m 80% down there and frankly I see them as little more than a lottery ticket now.
My experience with them and others does lead me to believe that the tide is going out on equity generally and small biotech particularly and almost nothing hemo does will have a big impact atm.
In short I wait for the tide to change (money flows in to small biotech) and then we might be rewarded for progress.